Clinical Trial Search

Primary: Percentage of Participants Who Gained at Least 15 Letters in BCVA at Week 24 as Measured by ETDRS Letter Score — 64; 9 percentage of participants — p=< 0.0001

Primary: Best Corrected Visual Acuity Change From Baseline at All Visits — 10.5; 15.1 ETDRS letters

Primary: Percentage of Participants Who Gained at Least 15 Letters in BCVA as Measured by ETDRS Letter Score Compared With Baseline at Week 24 With Discontinued Participants…

Primary: Total Number of Intravitreal Injections Over a 12 Month Period — 8.7; 9.5 injections

Primary: Visual Acuity — 16.8; 14.5; 19.1; 15.3 letters on ETDRS Visual Acuity Chart

Primary: Visual Acuity — 0.32; 0.44 logMAR units

Primary: Mean Change in Best Corrected Visual Acuity (BCVA) at Month 12 Compared to Baseline — 12.3 Letters

Primary: Change From Baseline in Visual Acuity Using Early Treatment Diabetic Retinopathy Study (ETDRS) Charts — 12.5; 14; 13.5 letters read correctly

Primary: The Primary Outcome is the Comparison Between the Minocycline and Placebo Groups of the Mean Change in Best-corrected Visual Acuity (BCVA) in the Study Eye at 12 Months…

Primary: The Proportion of Participants Who Gained ≥ 15 Letters in Best Corrected Visual Acuity (BCVA) on the Early Treatment Diabetic Retinopathy Score (ETDRS) Chart Compared to…

Primary: Average Change in Visual Acuity (Letters) From Baseline to Month 1 Through Month 3 — 11.3; -2.7 Letters — p=<0.001

Primary: Percentage of Participants With Best Corrected Visual Acuity (BCVA) of 20/40 or Better and Central Retinal Thickness (CRT) ≤250 µm on Time Domain (TD) Optical Coherence…

Primary: Change From Baseline in Best Corrected Visual Acuity (BCVA) in the Study Eye — 47.56; 5.09 Letters

Primary: Number of Participants Who Had a >30% Decrease in the Aqueous Levels of Various Vasoactive Proteins 4 Weeks After an Injection of Ozurdex — 7; 5; 7; 4 participants

Primary: Incidence and Severity of Ocular and Systemic Adverse Events — 1; 0; 0; 1 participants

Primary: Change in ETDRS Best Corrected Visual Acuity From Baseline at 54 Weeks — 14 ETDRS letters

Primary: Trend of Change From Baseline in the Best Corrected Visual Acuity (BCVA) Scores From Month 7 to Month 15 — 17.5; 19.7; 18.7; 21.0 Letters — p=0.5091

Primary: Incidence of Serious Adverse Events. — 17 number of serious adverse events

Primary: The Number of Study Participants Experiencing an Improvement by 15 or More Letters From Baseline in Best-corrected ETDRS Visual Acuity Score at the 12-month Visit — 5…

Primary: Mean Change From Baseline in Best Corrected Visual Acuity (BCVA) Score at 6 Months — 49.2; 47.4; 48.1; 0.8 Units on a scale — p=<0.0001

Primary: Mean Change in Best-corrected Visual Acuity (BCVA) in the Study Eye at 12 Months Compared to Baseline. — 5.3; 13.0 ETDRS letters

Primary: Change From Baseline in Best Corrected Visual Acuity (BCVA) at Month 6 — 51.90; 18.60 letters

Primary: Number of Patients With 15 or More Letter Improvement in Best Corrected Visual Acuity (BCVA) in the Study Eye — 53; 48; 38 Number of Participants

Primary: Cumulative Response Rate of 15 or More Letter Improvement — 0.101; 0.092; 0.045; 0.258 Kaplan-Meier Estimate

Primary: Average Change in Best Corrected Visual Acuity (BCVA) From Baseline to Month 1 Through Month 6 — 12.5; 5.0 Letters — p=<0.001

Primary: Number of Participants With Ocular Adverse Events in the Study Eye — 51; 64; 63; 60 participants

Primary: Mean Change From Baseline in Best-corrected Early Treatment Diabetic Retinopathy Study (ETDRS) Visual Acuity Letter Score at Month 6 — 18.9; 18.6 letters read

Primary: Change in Panretinal Leakage Index at Month 12 From Baseline — -3.14 percentage of region of interest in UWFA

Primary: Macular Function Using Microperimetry — 2.7; 12.7; 4.2; 10.7 dB

Primary: Change From Baseline in Best Corrected Visual Acuity (BCVA) — 56.6; 59.2; 7.9; 16.9 letters